Glioma

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This study tests a new treatment called BCB-276 for children and young adults with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. BCB-276 is made from a patient's own immune cells, which are modified in a lab to recognize and attack the cancer. The tr…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This study tests whether an investigational drug called HF1K16, when combined with the approved drug bevacizumab, can help people with recurrent or progressive glioma—a type of brain tumor. The trial enrolls about 30 adults whose tumors have returned or worsened after prior treat…

This early-phase study tests a new treatment for children and young adults with aggressive brain tumors called high-grade glioma and DIPG. The therapy uses the patient's own immune cells, modified in a lab to better recognize and attack tumor cells. The main goals are to see if t…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This trial tests a personalized vaccine called YS247 for people with recurrent glioblastoma, an aggressive brain cancer. The vaccine is made from each patient's own immune cells and designed to target unique markers on their tumor. The study aims to see if the vaccine is safe and…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This early-stage trial tests whether using focused ultrasound with microbubbles can temporarily open the blood-brain barrier, allowing the immunotherapy drug nivolumab to reach brain tumors more effectively. It includes 30 children and young adults with relapsed diffuse midline g…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This phase III trial compares a new type of MRI, called CEST MRI, to standard MRI for guiding surgery in 60 patients with newly diagnosed glioblastoma. The CEST MRI may detect tumor tissue that standard MRI misses, allowing surgeons to remove more of the cancer. The study will me…

This study tests an experimental drug called BMS-986504 in people with a rare cancer called malignant peripheral nerve sheath tumor (MPNST) that cannot be removed by surgery. Only people whose tumors are missing a gene called MTAP can join. The drug is taken daily by mouth, and t…

This study tests a virus called G207 combined with a small dose of radiation in children whose high-grade glioma has come back or is growing. The goal is to see if the treatment is safe and helps control the tumor. About 38 children will take part.

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study is for adolescents and young adults (ages 12-39) newly diagnosed with aggressive brain tumors called high-grade glioma or DIPG. The goal is to see if a combination of two immunotherapy drugs (relatlimab and nivolumab, sold as Opdualag) is safe and tolerable when given …

This early-phase trial tests a new combination for recurrent glioblastoma, a fast-growing brain tumor. The treatment pairs Actimab-A, a radioactive antibody that seeks out cancer cells, with cemiplimab, an immunotherapy that helps the immune system attack tumors. About 30 adults …

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This early-stage trial tests whether combining vorasidenib (a targeted therapy) with lomustine (a chemotherapy) is safe for people with recurrent IDH-mutant gliomas, a type of brain cancer. About 24 adults whose tumors have returned will receive different doses to find the best o…

This pilot study tests whether a device called NaviFUS, which uses ultrasound and microbubbles to temporarily open the blood-brain barrier, can safely help the drug bevacizumab reach recurrent glioblastoma tumors more effectively. Ten adults whose brain cancer has returned after …

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This study tests a new approach for recurrent glioblastoma, an aggressive brain cancer. It combines a minimally invasive laser that heats and destroys tumor tissue (LiTT) with an immunotherapy drug called cemiplimab, which helps the immune system attack cancer cells. About 99 par…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-phase trial tests a new personalized vaccine called Bvax, made from each patient's own cells, combined with standard chemoradiation for newly diagnosed glioblastoma. The study will enroll 25 people to check safety and see if the vaccine helps control the cancer. It is …

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This phase 2 trial tests a single dose of FG001, a fluorescent dye, in 76 adults with newly diagnosed high-grade glioma. The dye is given before surgery and glows under a special light, helping surgeons tell tumor from healthy tissue during removal. The study checks how well the …

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This trial tests whether adding mycophenolate mofetil, a drug usually used in organ transplants, to standard radiation and chemotherapy can help people with advanced glioblastoma live longer. About 422 participants will receive either the standard treatment or standard treatment …

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This early-phase study tests a new drug called MT-125 alongside standard chemoradiation in people newly diagnosed with a specific type of glioblastoma (MGMT methylated). The goal is to find a safe dose and see how well the body handles it. About 36 adults will take part, with the…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This study looks at a new way to give radiation to children with brain tumors that need whole-brain and whole-spine treatment. The technique, called vertebral body-sparing proton therapy, aims to protect the front of the spine bones to preserve bone marrow and growth. Researchers…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This early-stage trial tests a new approach for people with recurrent glioblastoma, an aggressive brain cancer that has come back after standard treatment. Researchers will give patients specially engineered natural killer (NK) cells, either directly into the brain or through an …

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This study tests two immunotherapy drugs, fianlimab and cemiplimab, in children and young adults with recurrent high-grade glioma or ependymoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. Participants will receive the drugs before an…

This phase III trial tests a new way to deliver radiation called TMPRT, which gives the total dose in short pulses with breaks in between, for people with a newly diagnosed, aggressive brain cancer (MGMT-unmethylated glioblastoma). About 398 adults will be randomly assigned to ge…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This study tests a new way to treat a rare and aggressive brain tumor called diffuse midline glioma (DMG) in the brainstem. The approach uses MRI-guided focused ultrasound to temporarily open the blood-brain barrier, allowing more of the chemotherapy drug temozolomide to reach th…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This early-stage study tests a new drug called BRiTE for safety in 18 adults with a specific type of glioblastoma (a fast-growing brain cancer). The drug is given as a continuous IV drip over 4 days each month. Only patients whose tumors have a specific genetic marker (EGFRvIII) …

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This study tests whether adding a shingles vaccine and, for some patients, specially grown immune cells (CMV-specific T cells) to standard surgery, radiation, and chemotherapy can help people with glioblastoma live longer. About 230 adults with this aggressive brain cancer will t…

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This phase 2 trial tests the drug mirdametinib, alone or with radiation, in people with NF1-related high-grade gliomas (aggressive brain tumors). It includes three groups: those with recurrent sporadic glioblastoma, newly diagnosed NF1-associated glioblastoma, and other NF1-relat…

This study tests a drug called tovorafenib in children and young adults (ages 1 to 39) newly diagnosed with aggressive brain tumors (high-grade glioma or DIPG) that have specific genetic changes. The goal is to see if the drug can help them live longer. About 79 participants will…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This early-stage trial tests a new drug called STAR-001 combined with the blood pressure medication spironolactone in about 68 people whose glioblastoma has returned after initial treatment. The goal is to see if the combination is safe and can shrink tumors. Participants receive…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This early-stage trial is testing a new treatment called CHT101 for adults with aggressive brain tumors that have returned or worsened despite standard care. CHT101 is a type of immune cell therapy (CAR T-cells) designed to recognize and attack tumor cells carrying a protein call…

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This pilot study tests a new radiation schedule for glioblastoma, a serious brain cancer. Instead of standard daily treatments over many weeks, patients receive a higher dose each day for fewer total sessions, combined with the chemotherapy drug temozolomide. The study aims to se…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This early-phase trial tests a new treatment for people whose malignant glioma (a type of brain cancer) has come back. The therapy uses the patient's own immune cells, modified to recognize and attack the cancer while also blocking a tumor defense mechanism. The study will enroll…

This early-stage trial tests a new treatment for recurrent high-grade glioma, an aggressive brain cancer. The approach uses a specially designed virus injected directly into the tumor to kill cancer cells and boost the immune system, combined with a PD-1 inhibitor drug that helps…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This early-stage trial tests whether two cancer drugs, cabozantinib and selumetinib, can safely shrink plexiform neurofibromas in people aged 16 and older with neurofibromatosis type 1 (NF1). About 30 participants will receive the combination daily. The study first finds the safe…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This early-stage trial tests whether using a special MRI-guided radiation machine (MR-Linac) can safely deliver higher, more targeted radiation doses to aggressive brain tumors (high-grade glioma). Twenty newly diagnosed patients will receive radiation twice a week for three week…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This early-stage study tests a new drug called FZ-AD005 in 40 people with aggressive brain tumors (high-grade glioma) that have come back or not responded to treatment. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to find the…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This study tests a new approach for a rare and aggressive brain tumor called butterfly glioblastoma, which crosses both sides of the brain and has a very poor outlook. The treatment combines open surgery to remove as much tumor as possible from one side, followed by a minimally i…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This early-phase trial tests a combination of three drugs—selumetinib, ZEN-3694, and durvalumab—in people with advanced sarcomas, including malignant peripheral nerve sheath tumors (MPNST) linked to NF1. The study first checks safety and dosing, then looks at whether the treatmen…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This study tests a new treatment called MT027 for people with recurrent glioblastoma, an aggressive brain cancer. MT027 uses specially engineered immune cells (UCAR-T cells) that are injected directly into the fluid around the brain. The trial will include 40 adults aged 18-70 an…

This study tests a drug called ADI-PEG 20, which breaks down an amino acid that some brain tumors need to grow. It is given alongside standard radiation and chemotherapy to children, adolescents, and young adults with newly diagnosed high-grade glioma. The goal is to see if this …

This early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …

This early-stage trial tests a new cell therapy called TH-CART-027 in 21 adults with recurrent grade 4 glioma, a very aggressive brain cancer. The therapy is given directly into the tumor or brain fluid. The main goal is to check safety and find the right dose, while also seeing …

This early-phase study tests whether combining focused ultrasound with the immunotherapy drug pembrolizumab is safe and feasible for people with recurrent glioblastoma, a severe brain cancer. Only 8 participants with a specific genetic feature (mismatch repair deficiency) will be…

This study tests whether using a smaller radiation target area after glioblastoma surgery can control the tumor while causing fewer side effects. About 79 patients will receive limited-field radiotherapy plus standard chemotherapy. The main goals are to see how many patients are …

This phase 2 trial tests whether placing tiny chemotherapy-releasing seeds directly into the brain after tumor removal can help control glioblastoma, an aggressive brain cancer. About 147 adults with either recurrent or newly diagnosed glioblastoma will receive the seeds plus sta…

This phase II trial tests a personalized dendritic cell vaccine (ZSNeo-DC1.1) combined with standard chemotherapy (temozolomide) in 78 adults with newly diagnosed glioblastoma. Participants receive the vaccine as shots during chemo after surgery and radiation. The goal is to see …

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This study tests a new treatment called Cerebraca Wafer for people with recurrent glioblastoma, a serious brain cancer. The wafer is placed in the brain during surgery and is followed by standard chemotherapy. The goal is to see if it helps people live longer and controls the dis…

This early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This phase 2 trial tests whether adding a cancer vaccine (UCPVax) with or without an immunotherapy drug (pembrolizumab) to standard treatment can help people with a newly diagnosed, aggressive type of glioblastoma live longer. About 98 adults whose tumors have a specific genetic …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This early study tests a new approach for people with slow-growing brain tumors located in areas that control movement. A small device placed on the skull delivers mild electrical stimulation while patients do physical therapy, aiming to retrain the brain so that critical functio…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This early-stage study tests an experimental drug called gallium maltolate in 15 children whose high-grade glioma or atypical teratoid rhabdoid tumor has returned or not responded to treatment. The main goals are to find safe doses and understand side effects. Everyone receives t…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This study tests a daily pill called vorasidenib in 10 teenagers (ages 12 to 17) with a slow-growing brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). The goal is to see if the drug is safe, how it affects growth and development, and whether it can…

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This early-phase trial tests a new type of immunotherapy for recurrent glioblastoma, an aggressive brain cancer. The treatment uses a patient's own immune cells, engineered to target a protein called EGFRvIII found on tumor cells, and modified to work better in the tumor's enviro…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…

This early-stage trial tests a modified herpes virus (C5252) injected directly into the brain tumor cavity of 36 adults with recurrent high-grade glioma who have run out of standard options. The goal is to see if the virus is safe and can help control the disease. Participants wi…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study tests whether adding NG101m capsules to standard chemoradiation helps people with newly diagnosed glioblastoma live longer. About 52 adults will receive NG101m alongside usual care. The goal is to see if the combination is safe and improves 2-year survival.

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…

This phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation affects heart rhythm in children aged 3–21 with newly diagnosed diffuse intrinsic brainstem glioma. The study will enroll 30 participants and monitor heart electrical ac…

This phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation therapy helps people aged 3 and older with a newly diagnosed, aggressive brainstem tumor live longer. About 92 participants will be randomly assigned to get either radia…

This study tests a new way to deliver radiation therapy for people with diffuse glioma, a type of brain tumor. Instead of giving the same dose throughout treatment, doctors will use MRI and PET scans taken during treatment to adjust the radiation dose to target resistant areas an…

This early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…

This study tests whether oxygen-enhanced MRI (OE-MRI) can identify low-oxygen (hypoxic) regions in high-grade gliomas, the most common and aggressive adult brain cancers. Twenty-five patients will undergo OE-MRI scans before, during, and after standard radiotherapy. Researchers w…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

This early-phase study will test two radioactive tracers designed to light up certain solid tumors on scans. Twenty adults with breast, head and neck, pancreatic cancer, or glioma will receive an injection of the tracers and then undergo PET/CT and SPECT/CT imaging. The goal is t…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This first-in-human study will test a new radioactive imaging agent called MeFAMP to see if it can safely and accurately detect brain tumors using PET scans. The study includes 28 people: healthy volunteers and patients with recurrent high-grade glioma or brain metastases from ot…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study tests whether drawing blood directly from veins inside the brain can safely diagnose high-grade glioma, a type of brain cancer. Researchers will compare this liquid biopsy to traditional surgical biopsy. Only 20 adults with suspected or confirmed brain cancer will part…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This early-stage trial tests a fluorescent dye called SBK2-ICG in 12 adults with untreated malignant brain tumors. The dye is given before surgery to see if it can make tumor edges glow, helping surgeons remove as much tumor as possible while protecting healthy brain. The main go…

This trial tests a new AI device that helps surgeons see brain tumors on ultrasound images during surgery. The AI highlights tumor tissue in real time, which may help remove more of the tumor while protecting healthy brain. The study involves 100 adults scheduled for brain tumor …

This study tests a fast genetic test (UR-ddPCR) that checks for IDH1-mutant tumor cells in brain tissue during surgery. If the test finds leftover cancer, the surgeon can remove more tissue right away. The trial will enroll 105 adults with newly diagnosed IDH-mutant glioma at NYU…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests a new group self-management program for adults with brain cancer. The goal is to see if the program is practical and helps improve mental health and quality of life more than standard care. Researchers will compare changes in well-being between the group program …

This study tests a stepped-care model to support relatives of people with acquired brain injury or malignant brain tumor. The model offers basic support to all, with extra help for those who need it, based on screening. Researchers will measure changes in caregiver burden and wel…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This early-stage study tests whether a special MRI that highlights acidic areas can help surgeons see and remove more of an aggressive brain tumor called glioblastoma. The study involves 12 VA patients with newly diagnosed or recurrent glioblastoma. The main goal is to check if t…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study tests whether playing virtual reality games can help brain cancer survivors who have mild memory and thinking problems after treatment. About 40 adults who finished cancer therapy within the last two years will either use VR games or do paper word puzzles for four week…

This study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study compares a new type of brain scan—watching movie clips during functional MRI (fMRI)—to standard task-based fMRI for mapping language areas in people with brain tumors (gliomas). The goal is to see if the simpler movie-watching method works as well or better for helping…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study looks at how glioblastoma, a serious brain cancer, changes the way brain cells communicate and use energy. Researchers will use special PET and MRI scans to map these changes in 80 adults before and after surgery. The goal is to link scan results with thinking and memo…

This study will test whether a special brain scan called magnetoencephalography (MEG) can detect electrical differences within gliomas, the most common malignant brain tumors in adults. Researchers will scan 60 newly diagnosed patients before surgery to see if MEG can identify mo…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study tests a lab technique called pharmacoscopy that analyzes a patient's tumor tissue to find which drugs might work best for them. It includes 40 adults with various aggressive or rare brain tumors that have not responded to standard treatments. The main goal is to see if…

This study looks at how the immune system changes in people with glioblastoma, an aggressive brain cancer, after they have surgery and chemotherapy. Researchers will take blood samples over six months to measure immune cells and signals. The goal is to understand the body's immun…

This study tests whether using MRI scans to plan radiotherapy is better than using CT scans alone. Researchers will work with up to 150 cancer patients and 15 healthy volunteers to see if MRI can make treatment more precise and reduce side effects. The goal is to improve how tumo…

This study tests a new type of MRI called Field-Cycling Imaging (FCI) to see if it can tell the difference between real tumor growth and pseudo-progression (which looks like tumor but isn't) in adults with glioblastoma. Eighteen patients will get both a standard MRI and an FCI sc…

This study tests whether special MRI scans can spot where brain tumors have spread into nearby healthy tissue, which standard scans miss. About 20 adults with suspected high-grade glioma will get extra scans before surgery. The results will be compared to tissue samples to see if…

This early-stage trial will test whether an oral drug called gallium maltolate can reach brain tumors in people with recurrent glioblastoma. Eight participants will take the drug for about two weeks before surgery, and researchers will measure gallium levels in the removed tumor …

This study tests whether real-time fMRI neurofeedback can help people with brain tumors (gliomas) shift language activity away from the tumor area before surgery. Only 4 participants will be enrolled to see if the approach is feasible, safe, and acceptable. It is a very early, sm…

This early study tests whether a small device can safely collect fluid from the brain during planned surgery for glioma or epilepsy. Six participants will have the device placed temporarily during their operation. The goal is to see if the device works and is safe, not to treat t…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study looks at how male hormones (androgens) influence the immune cells around glioblastoma tumors, the most common and aggressive brain cancer in adults. Researchers will collect blood, saliva, and stool samples from 40 newly diagnosed patients before and after standard che…

This study looks at whether a special PET scan (18F-AGX) can detect early changes in brain tumor activity in adults with slow-growing IDH-mutant gliomas who are taking the drug Vorasidenib. Ten participants will get the drug daily for about a year and have multiple PET and MRI sc…

This study tests whether physical therapy, alone or with brain stimulation, can help rewire the brain before surgery for high-grade glioma near the motor area. About 63 adults with preserved movement will be randomly assigned to standard care, therapy, or therapy plus stimulation…

This study will test whether a mobile app called Resilience PRO can help monitor symptoms and quality of life in 80 adults with IDH-mutated glioma who are starting a new systemic treatment. Participants will use the app to report side effects and complete questionnaires every two…

This study tests giving chemotherapy before radiation for people with high-grade gliomas, a type of aggressive brain tumor. The goal is to see if this approach works well and makes MRI scans easier to read, since radiation can change how the brain looks. About 70 adults aged 18-8…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study tests a special microscope accessory called GLOW400 that helps surgeons see glowing brain tumors during surgery. About 37 adults with suspected high-grade gliomas will take part. Surgeons will rate how well the device shows tumor fluorescence and image quality. The goa…

This study follows 93 children aged 5-18 with brain tumors who are receiving radiation therapy. Researchers will track their nutrition and quality of life over time to see how they are connected. The goal is to create a nutrition plan and early warning system to help these childr…

This study tests how well the MyVeo surgical headset shows surgical details during routine brain, spine, ear-nose-throat, or reconstructive surgeries. Surgeons will rate image quality, comfort, and safety while using the device. About 32 patients will take part, and no extra proc…

This study will include 30 people newly diagnosed with glioblastoma, the most common and aggressive brain tumor. Researchers will use a special MRI technique called magnetic resonance spectroscopy (MRS) to measure chemicals in the tumor, and also test blood for certain markers. T…

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…

This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …

This study will follow 50 adults with glioblastoma, an aggressive brain cancer, to see how the amount of tumor removed during surgery affects how long they live. All patients will receive standard radiation and chemotherapy after surgery. The goal is to better understand which su…

This study will analyze blood and tumor samples from 45 adults with glioblastoma to understand why this aggressive brain cancer recurs. Researchers will look at molecular, immune, and metabolic changes in tumors from both new and recurrent cases. The goal is to find new targets f…

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This study tests a special camera attached to a surgical microscope to see if it can better detect glioma tumor cells during brain surgery. Researchers will observe 80 adults with suspected high-grade gliomas. The goal is to improve how surgeons see tumor tissue, not to test a ne…

This study will follow 100 adults with glioblastoma, an aggressive brain cancer, to understand which factors influence survival. Researchers will collect data on patient characteristics, tumor features, surgical methods, and outcomes. The goal is to identify the best surgical str…

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…